Clinical bottom line
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and sinus tracts, primarily affecting intertriginous areas. Recent advancements in systemic therapies have shown promise in managing moderate to severe HS, offering new options beyond traditional treatments such as antibiotics and surgery. This evidence digest reviews the efficacy and safety of these emerging systemic treatments, focusing on biologics and small molecules that target specific inflammatory pathways.
What the evidence shows
Recent studies have highlighted the efficacy of biologics, particularly tumor necrosis factor (TNF) inhibitors and interleukin (IL) inhibitors, in treating moderate to severe HS. Adalimumab, a TNF inhibitor, is currently the only FDA-approved biologic for HS. A pivotal phase 3 trial demonstrated its efficacy, with a significant proportion of patients achieving a 50% reduction in abscess and inflammatory nodule count without an increase in abscesses or draining fistulas [1]. More recent trials have explored IL-17 inhibitors, such as secukinumab, which have shown promising results in reducing HS lesions and improving patient-reported outcomes [2].
Small molecule inhibitors, such as Janus kinase (JAK) inhibitors, are also being investigated for HS. Early-phase trials suggest that these agents may reduce inflammation and lesion count in HS patients, although further research is needed to confirm their long-term efficacy and safety [3].
Caveats and uncertainty
While biologics and small molecules offer new hope for HS patients, several caveats remain. The long-term safety profiles of these treatments are still being established, and there is a need for more extensive real-world data to confirm their efficacy across diverse patient populations. Additionally, the high cost of biologics may limit accessibility for some patients, posing a challenge for widespread adoption.
The heterogeneity of HS, including variability in disease severity and patient response to treatment, complicates the development of standardized treatment protocols. Personalized treatment strategies, potentially guided by biomarkers, may be necessary to optimize outcomes for individual patients.
How this may change practice
The introduction of new systemic treatments for HS has the potential to significantly alter clinical practice by providing more effective management options for patients with moderate to severe disease. These therapies may reduce the reliance on surgical interventions and improve quality of life for patients who have not responded to traditional treatments. Clinicians should remain informed about the latest evidence and consider these emerging therapies as part of a comprehensive, individualized treatment plan for HS.